METTL3 and gastric cancer: Collectively, the above results show that the high degree of m6A modification and increased protein expression mediated by METTL3 are significantly correlated with the prognosis and antitumor drugs of GC patients, signifying that they are promising novel biomarkers and potential clinical therapeutic targets for GC.